Our analysis demonstrates that treatment with ponatinib at an initial dose of 45 mg supports high response rates and survival outcomes among patients with CP‐CML resistant to 2G TKIs, regardless of BCR::ABL1 mutation status. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.